Post Content
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge in total revenue to $502.1 million. This was driven largely by the commercial success of its flagship product, Attruby. In Q4 alone, Attruby generated $146 million in net product revenue, reflecting a 35% increase over Q3. This growth was supported by 7,804 new patient starts and high levels of patient persistence.
The company achieved significant clinical milestones with three positive Phase 3 readouts in late 2025: Encaleret for ADH1, BBP-418 for LGMD2I, and Infigratinib for achondroplasia. These successes position BridgeBio to transition from a single-product company to one with potentially six approved medicines by the end of its first decade. NDAs for both Encaleret and BBP-418 are expected in H1 2026, with US launches targeted for late 2026 or early 2027.
Management highlighted that Attruby’s near-complete stabilization of transthyretin serves as a key clinical differentiator that should protect its market share even as potential generic competitors for tafamidis emerge. While the net loss for the year widened to $724.9 million, BridgeBio Pharma Inc. (NASDAQ:BBIO) expects cash burn to stabilize and eventually decrease as Attruby’s margins expand and new products enter the market.
BridgeBio Pharma Inc. (NASDAQ:BBIO) is a biopharmaceutical company that discovers, develops, and delivers medicines for patients with genetic diseases.
While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Best Stocks for Beginners with Little Money in 2026.
Disclosure: None. Follow Insider Monkey on Google News.